<DOC>
	<DOCNO>NCT02770989</DOCNO>
	<brief_summary>This study prospective , non-randomized , single arm , multicenter , CE mark trial patient paroxysmal atrial fibrillation undergo ablation cardiac tissue near PV .</brief_summary>
	<brief_title>Vimecon CAI Trial Interventional Treatment Paroxysmal Atrial Fibrillation ( AF )</brief_title>
	<detailed_description>The objective clinical investigation confirm safety performance Vimecon® Laser Cardiac Ablation Instrument create scar tissue within cardiac wall treatment atrial fibrillation . Up 66 patient paroxysmal atrial fibrillation refractory least one antiarrhythmic medication ( Class I III ) enrol . expect 10 % dropout ; 59 per protocol patient require . The study duration 18 month 6 month enrollment period 12 month follow-up . Interim follow-up visit post procedure , 1 Month , 3 Months , 6 Months 12 Months . The baseline follow test standard care . Additional optional test esophageal endoscopy determination potential fistula formation cerebral MRI micro embolism post treatment .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Aged 18 75 year . 2 . Patients intention treat paroxysmal atrial fibrillation . AND unresponsive ≥1 antiarrhythmic drug ( class I III ) AND least 2 episode last 12 month , 1 document . 3 . Patient anticoagulation therapy accord international guideline ( per ACC/AHA//ESC Practice Guidelines ) 4 . Left atrial ( LA ) size &lt; 50 mm 5 . RSPV ( right superior Pulmonary Vein ) ≤ 30mm 6 . Symptomatic AF ( EHRAScore ≥ 2 ) 7 . Accessibility femoral vein pulmonary vein 8 . All patient willing comply study protocol least 12 month 1 . Inability give write informed consent 2 . NYHA Class III IV 3 . Hyperthyroidism 4 . Left Atrial Thrombus formation 5 . Structural heart disease disturb accessibility AF ablation 6 . Valvular AF 7 . EHRAScore 1 8 . Any valvular dysfunction II° 9 . Previous thoracic and/or cardiac surgery include restrict : Implanted AICD Implanted Pacemaker Implanted PFO / ASD Closure Device Implanted Atrial Appendage closure Device Implanted biological artificial Heart Valve 10 . Impaired leave ventricular function ejection fraction le 35 % 11 . Kidney dysfunction &gt; Class III GFR le 35 mL per minute 12 . Patient suffer TIA Stroke within last 3 month 13 . Pregnancy Breastfeeding Women 14 . Previous interatrial septal patch surgical intervention adjacent intro atrial septum 15 . Known suspected atrial myoma 16 . Life expectancy le 12 month 17 . Subject comorbid condition place subject unacceptable risk ( e.g. , severe chronic obstructive pulmonary disease , hepatic failure , immunosuppressive abnormality , nervous system disease hematological abnormality . ) 18 . Contraindicated protocol define anticoagulation plan ( per ACC/AHA//ESC Practice Guidelines ) 19 . Patients know allergic reaction local anesthetic , sedative , xray dye , heparin , protamine , agent administer procedure . 20 . Chronic heart failure 21 . Enrolled another clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cardiac Ablation</keyword>
	<keyword>Safety</keyword>
	<keyword>Performance</keyword>
	<keyword>Laser</keyword>
</DOC>